Abstract
Background and Objective
China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of screening and treatment are needed to achieve the WHO 2030 hepatitis C elimination targets. We aimed to evaluate the impact of scaling up interventions on the hepatitis C epidemic and determine how and at what cost these elimination targets could be achieved for the whole population in China.
Methods
We developed a compartmental model incorporating HCV transmission, disease progression, and care cascade for the whole population in China, calibrated with data on demographics, injecting drug use, HCV prevalence, and treatments. Five different scenarios were evaluated for effects and costs for 2022–2030. All costs were converted to 2021 US dollar (USD) and discounted at an annual rate of 5%. One-way sensitivity analyses were conducted to assess the robustness of the model.
Results
Under the status quo scenario, the incidence of hepatitis C is projected to increase from 60.39 (57.60–63.45) per 100,000 person-years in 2022 to 68.72 (65.3–73.97) per 100,000 person-years in 2030, and 2.52 million (1.94–3.07 million) infected patients are projected to die between 2022 and 2030, of which 0.76 (0.61–1.08) million will die due to hepatitis C. By increasing primary screening to 10%, conducting regular rescreening (annually for PWID and every 5 years for the general population) and treating 90% of patients diagnosed, the incidence would be reduced by 88.15% (86.61–89.45%) and hepatitis C-related mortality by 60.5% (52.62–65.54%) by 2030, compared with 2015 levels. This strategy would cost USD 52.78 (USD 43.93–58.53) billion.
Conclusions
Without changes in HCV prevention and control policy, the disease burden of HCV in China will increase dramatically. To achieve the hepatitis C elimination targets, China needs to sufficiently scale up screening and treatment.
China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of screening and treatment are needed to achieve the WHO 2030 hepatitis C elimination targets. We aimed to evaluate the impact of scaling up interventions on the hepatitis C epidemic and determine how and at what cost these elimination targets could be achieved for the whole population in China.
Methods
We developed a compartmental model incorporating HCV transmission, disease progression, and care cascade for the whole population in China, calibrated with data on demographics, injecting drug use, HCV prevalence, and treatments. Five different scenarios were evaluated for effects and costs for 2022–2030. All costs were converted to 2021 US dollar (USD) and discounted at an annual rate of 5%. One-way sensitivity analyses were conducted to assess the robustness of the model.
Results
Under the status quo scenario, the incidence of hepatitis C is projected to increase from 60.39 (57.60–63.45) per 100,000 person-years in 2022 to 68.72 (65.3–73.97) per 100,000 person-years in 2030, and 2.52 million (1.94–3.07 million) infected patients are projected to die between 2022 and 2030, of which 0.76 (0.61–1.08) million will die due to hepatitis C. By increasing primary screening to 10%, conducting regular rescreening (annually for PWID and every 5 years for the general population) and treating 90% of patients diagnosed, the incidence would be reduced by 88.15% (86.61–89.45%) and hepatitis C-related mortality by 60.5% (52.62–65.54%) by 2030, compared with 2015 levels. This strategy would cost USD 52.78 (USD 43.93–58.53) billion.
Conclusions
Without changes in HCV prevention and control policy, the disease burden of HCV in China will increase dramatically. To achieve the hepatitis C elimination targets, China needs to sufficiently scale up screening and treatment.
| Original language | English |
|---|---|
| Number of pages | 13 |
| Journal | PharmacoEconomics |
| Early online date | 2 Sept 2024 |
| DOIs | |
| Publication status | E-pub ahead of print - 2 Sept 2024 |
Bibliographical note
Publisher Copyright:© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
Access to Document
- Full-text PDF (accepted manuscript)
This is the accepted author manuscript (AAM) of the article which has been made Open Access under the University of Bristol's Scholarly Works Policy. The final published version (Version of Record) can be found on the publisher's website. The copyright of any third-party content, such as images, remains with the copyright holder.